Investigator Initiated Studies (IIS)
Investigator Initiated Studies (IIS) supports scientists and clinical researchers pursuing independent clinical, observational, and outcomes research to explore questions or develop new treatment concepts.
Funder: Boehringer Ingelheim
Due Dates: Rolling review (synopses and full proposals)
Funding Amounts: Financial support and/or study drugs for approved studies
Summary: Supports unsolicited, independently sponsored clinical, observational, real-world evidence, and non-commercial health economics and outcomes research.
Key Information: A non-commercial sponsor must retain sole responsibility for the study; budgets cannot include direct investigator salary support.
Description
Boehringer Ingelheim’s Investigator Initiated Studies (IIS) program supports scientists and clinical researchers proposing and conducting their own independent research. It sits within the company’s External Research Studies framework, covering externally regulated and externally legally sponsored research. Eligible work includes pre- and post-marketing interventional clinical trials, non-interventional observational and real-world evidence studies, and non-commercial health economics and outcomes research.
IIS are generally exploratory studies or studies that may lead to new treatment concepts, rather than registration studies. Unlike External Collaborative Research, IIS are proposed and conducted independently: Boehringer Ingelheim does not influence the study proposal or provide operational support. The independent sponsor remains responsible for initiating, managing, financing, and operating the study.
